Loading
A phase 1/2 trial of Zongertinib, Trastuzumab deruxtecan, Trastuzumab emtansine in colorectal cancer, run by Boehringer Ingelheim, now recruiting.
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread is a phase 1/2 interventional study registered as NCT06324357 by Boehringer Ingelheim, with 768 participants planned, started 2024-06-28 and due to reach its primary completion in 2029-01-08. Interventions recorded: Zongertinib, Trastuzumab deruxtecan, Trastuzumab emtansine, Trastuzumab, Capecitabine. Conditions listed: Metastatic Breast Cancer, Metastatic Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Esophageal Adenocarcinoma. No results are recorded here; the registry entry is the source.
Shares Zongertinib, Boehringer Ingelheim, Small-molecule kinase inhibitors.
Shares Zongertinib, Boehringer Ingelheim, Small-molecule kinase inhibitors.
Shares Zongertinib, Boehringer Ingelheim, Small-molecule kinase inhibitors.
Shares HER2-amplified colorectal cancer, Trastuzumab, Colorectal cancer.
Shares Zongertinib, Boehringer Ingelheim, Trastuzumab deruxtecan, Small-molecule kinase inhibitors.
Shares Zongertinib, Boehringer Ingelheim, Small-molecule kinase inhibitors.
Shares HER2-amplified colorectal cancer, Trastuzumab, FOLFOX (5-FU, leucovorin, oxaliplatin), Small-molecule kinase inhibitors.
Shares HER2-amplified colorectal cancer, FOLFOX (5-FU, leucovorin, oxaliplatin), Capecitabine.